Abstract A32: GIGA-564, a Third Generation Anti-Ctla-4 with Minimal Ability to Block CTLA-4 Binding to B7 Ligands, Has Enhanced Efficacy but Reduced Toxicity Compared to Ipilimumab in Pre-Clinical ModelsErica L. Stone,Kyle P. Carter,Ellen K. Wagner,Michael A. Asensio,Emily Benzie,Yao Chiang,Garry L. Coles,Chelsea Edgar,Bishal K. Gautam,Ashley Gras,Jackson Leong,Renee Leong,Vishal A. Manickam,Rena A. Mizrahi,Ariel R. Niedecken,Jasmeen Saini,Savreet K. Sandhu,Jan Fredrick Simons,Kacy Stadtmiller,Brendan Tinsley,LaRee Tracy,Nicholas Wayham,Yoong Wearn Lim,Adam S. Adler,David S. JohnsonCancer Immunology Research（2022）引用 0|浏览2AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
